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Overexpression of the Axl tyrosine kinase receptor in cutaneous
SCC-derived cell lines and tumours
J Green1,2,3, M Ikram1,2, J Vyas2, N Patel2, CM Proby1,2, L Ghali1,2, IM Leigh1,2, EA O’Toole2 and A Storey*,1,2
1Cancer Research UK, Skin Tumour Laboratory, London E1 2AT, UK; 2Centre for Cutaneous Research, Institute for Cell and Molecular Science, 4 Newark
Street, London E1 2AT, UK
The molecular mechanisms that underlie the development of squamous cell skin cancers (SSC) are poorly understood. We have
used oligonucleotide microarrays to compare the differences in cellular gene expression between a series of keratinocyte cell that
mimic disease progression with the aim of identifying genes that may potentially contribute towards squamous cell carcinoma (SCC)
progression in vivo, and in particular to identify markers that may serve as potential therapeutic targets for SCC treatment. Gene
expression differences were corroborated by polymerase chain reaction and Western blotting. We identified Axl, a receptor tyrosine
kinase with transforming potential that has also been shown to have a role in cell survival, adhesion and chemotaxis, was upregulated
in vitro in SCC-derived cells compared to premalignant cells. Extending the investigation to tumour biopsies showed that the Axl
protein was overexpressed in vivo in a series of SCCs.
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Non-melanoma skin cancer (NMSC) is the most prevalent human
cancer, with about 1 million cases in the USA and 460 000 cases
occurring annually in the UK. Basal cell carcinoma (BCC) is the
most common NMSC, whereas squamous cell carcinoma (SCC)
accounts for 20% of all cutaneous malignancies. Squamous cell
carcinomas typically arise on sun-exposed body sites, and the
incidence in Europe, North America and Australia ranges from 50
to 170 cases per 100 000 individuals (Holme et al, 2000; Diepgen
and Mahler, 2002). Cutaneous SCCs are usually treated by excision;
however, they do have the potential to recur locally and, in some
cases, to metastasize. Currently, the most common prognostic
indicators are histologic subtype and tumour size.
In contrast to BCC development, where mutations in the
patched signalling pathway are associated with BCC formation
(Johnson et al, 1996), the current knowledge on factors that are
involved in the de novo development and progression of SCC is
relatively sparse.
To identify genes that are differentially expressed in SCC
compared to normal skin, we have focused in particular on genes
encoding cell surface receptors, as overexpression of the encoded
protein may serve either as a useful biomarker or a potential target
for therapeutic intervention. We have made use of a unique series
of cutaneous SCC cell lines derived from an immunosuppressed
patient representing different stages of malignant transformation
(Proby et al, 2000), that serve as a model in which to study the
changes in gene expression that occur in the transition from
premalignant cells to SCC and finally to a metastatic tumour. They
were established from forehead skin (PM1), a primary SCC
(MET1) and an associated lymph node metastasis (MET4).
Affymetrix GeneChip arrays were used to compare the expression
profile of PM1 with two malignant cell lines (MET1 and MET4).
Most interestingly, the expression analysis revealed upregulation
of Axl, a transmembrane receptor tyrosine kinase with transform-
ing potential (O’Bryan et al, 1991) and is an intriguing candidate
for involvement in SCC development and progression. Further
immunohistochemical analysis of Axl protein expression in a panel
of SCCs revealed that Axl was frequently overexpressed in SCCs
compared to BCC or normal skin.
MATERIALS AND METHODS
Cell culture
Early passage (less than p16) PM1, MET1 and MET4 keratinocyte
cell lines were grown with an irradiated fibroblast feeder layer
in Dulbecco’s modified Eagle’s medium plus HAMS F12 medium
containing 10% foetal calf serum essentially as described
(Rheinwald and Green, 1975).
Microarray experiments and semi-quantitative reverse
transcription–polymerase chain reaction
Briefly, total RNA was extracted from 70–80% confluent PM1,
MET1 and MET4 cell lines using TRIZOL Reagent (Invitrogen-
15596, Paisley, UK) and was used to generate labelled probes as
per manufacturer’s instructions. These were used to hybridise the
U133A Gene Chips using an Affymetrix Fluidics station 400. Three
biological replicates were performed for each of the three cell lines.
Full details of the methodology and statistical analysis can be
found in Supplementary Material.
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Table 1 Gene expression profile using Affymetrix arrays of genes differentially expressed in MET1 and MET4 vs PM1cell line and MET1 vs MET4.
MET1 vs PM1 MET4 vs PM1 MET1 vs MET4
Genbank Common Function Fold +/ Fold +/ Fold +/
Ubiquitin cycle/proteolysis and peptidolysis
AA020826 CTSB Cathepsin B 5
Transport
N74607 AQP3 Aquaporin 3 10 6
AF201942 NXT2 Nuclear transport factor 2-like export factor 2 8
Transcription/replication
NM_004364 CEBPA CCAAT/enhancer binding protein (C/EBP), alpha 10
H94842 HOXA11 Homeo box A11 6 8
BC005342 NSBP1 Nucleosomal-binding protein 1 16
NM_016594 FKBP11 FK506-binding protein 11, 19 kDa 5
AB046692 AOX1 Aldehyde oxidase 1 8
Signalling
NM_006176 NRGN Neurogranin (protein kinase C substrate, RC3) 11
NM_001945 DTR Diphtheria toxin receptor) 16 22
AA464753 PDAP1 Homo sapiens, clone IMAGE:3457786 8
M14333 FYN FYN oncogene related to SRC, FGR, YES 5
NM_004335 BST2 Bone marrow stromal cell antigen 2 16
NM_013447 EMR2 egf-like, hormone receptor-like sequence 2 6
NM_003020 SGNE1 Secretory granule, neuroendocrine protein 1
(7B2 protein) 5
AI439556 TXNIP Thioredoxin interacting protein 5
Development
NM_000366 TPM1 Tropomyosin 1 (alpha) 6
NM_003412 ZIC1 Zic family member 1 (odd-paired homolog, Drosophila) 33 39
U61276 JAG1 Jagged 1 (Alagille syndrome) 5
NM_014556 EVC Ellis van Creveld syndrome 10
Growth factor/chemokine/cytokine/inflammation/immune response
NM_002658 PLAU Plasminogen activator, urokinase 6
AL573058 C1R Complement component 1, r subcomponent 13 10
M92934 CTGF Connective tissue growth factor 13
NM_003596 TPST1 Tyrosylprotein sulfotransferase 1 8
NM_013314 BLNK B-cell linker 6
NM_002964 S100A8 S100 calcium-binding protein A8 (calgranulin A) 5
NM_002852 PTX3 Pentaxin-related gene, rapidly induced by IL-1 beta 8
M69176 CEACAM1 Carcinoembryonic antigen-related cell adhesion molecule 1 6
NM_006379 SEMA3C Semaphorin 3C 10
NM_002053 GBP1 Guanylate-binding protein 1, interferon-inducible, 67 kDa 7
NM_014391 ANKRD1 Cardiac ankyrin repeat protein 8
NM_000963 PTGS2 Prostaglandin-endoperoxide synthase 2 5 16
L27624 TFPI2 Tissue factor pathway inhibitor 2 9
BG166705 CXCL5 Chemokine (C-X-C motif) ligand 5 227
Cell cycle/oncogene/tumour suppressor
NM_001759 CCND2 Cyclin D2 7 8
M15329 IL1A Interleukin 1, alpha 5
NM_005504 BCAT1 Branched chain aminotransferase 1, cytosolic 11
NM_000393 COL5A2 Collagen, type V, alpha 2 44 23
NM_000584 IL8 Interleukin 8 112 32
Metabolism/stress response
NM_005965 MYLK Myosin, light polypeptide kinase 7 7
NM_016816 OAS1 2’,5’-oligoadenylate synthetase 1, 40/46 kDa 5
AW614435 UROD Uroporphyrinogen decarboxylase 16
AV704962 SC4MOL Sterol-C4-methyl oxidase-like 7
NM_004265 FADS2 Fatty acid desaturase 2 4 5
NM_018192 LEPREL1 Leprecan-like 1 10 15
NM_007034 DNAJB4 DnaJ (Hsp40) homolog, subfamily B, member 4 5
AF054841 TM4SF7 Transmembrane 4 superfamily member 7 5 6
NM_000050 ASS Argininosuccinate synthetase 5
Cytoskeleton/cell adhesion
NM_002628 PFN2 Profilin 2 25 15
U76549 KRT8 Keratin 8 6
AI831452 KRT6B Keratin 6B 5
NM_004791 ITGBL1 Integrin, beta-like 1 (with EGF-like repeat domains) 7 15
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Quantitative reverse transcription –polymerase chain reaction
(RT—PCR) was performed to validate data from GeneChip
experiments and was performed using an OPTICONt 2 Contin-
uous Fluorescence Detection System (Bio-Rad) on the three
replicate samples used in the GeneChip analysis. Full details of
the Q– PCR conditions are given in Supplementary Material.
The primer pairs used for amplification of the selected targets
were:
Axl: GAGAACATTAGTGCTACGCGGAA/
CCTTAGCCCTATGTCCATTAGCA
G6PDH: GTTCCGTGAGGACCAGATCTAC/
GGCTCCTTGAAGGTGAGGATAA
Antibodies and immunohistochemistry
Antibodies used in this study were anti-Axl (C-20), anti-Gas 6
(N-20), (Santa Cruz Biotechnology Inc., Palo Alto, CA, USA), anti-
a tubulin (Ab-1, Oncogene Science, Cambridge, MA, USA).
Archival paraffin blocks were used for immunohistochemistry;
ethical approval for this study was obtained from the East London
and City Health Authority Research Ethics Committee.
Axl expression was examined using standard immunohisto-
chemical techniques using 4 mm thick sections that had been
deparaffinized, then blocked with rabbit serum and incubated with
a goat polyclonal anti-Axl antibody. The sections were then
processed as described (Jackson et al, 2002). Quantitative analysis
of Axl staining was performed using KS400 version 3.0 imaging
software (Carl Zeiss Ltd, Welwyn Garden City, UK). The
percentage of cells expressing Axl was calculated in four
representative high-power fields. Statistical analysis was performed
using Arcus Quickstat (Statsdirect, Sale, UK, Biomedical version
1.1) and JMPr, SAS Inc. (Karey, NC, USA). For Western blot
analysis was performed as described (Jackson et al, 2002), signals
were detected using ECLþ (Amersham Biosciences UK Ltd,
Bucks, UK).
RESULTS
Gene expression profiles in premalignant and malignant
keratinocyte lines
We compared the relative gene expression levels of the MET1 and
MET4 lines with PM1, and also compared expression in MET4 with
the solid tumour from which it appears to have originated, MET1
(Popp et al, 2000). The profiling revealed that 276 genes were
statistically differentially expressed in PM1 cells compared to
MET1 and MET4 cells (P¼ 0.0001). For practical reasons, we have
applied an arbitrary filter level of five-fold changes in the ratio of
expression levels; this relatively high cutoff point was used with a
Table 1 (Continued )
MET1 vs PM1 MET4 vs PM1 MET1 vs MET4
Genbank Common Function Fold +/ Fold +/ Fold +/
AI806793 COL8A2 Collagen, type VIII, alpha 2 8
AI922599 VIM Vimentin 5
NM_000422 KRT17 Keratin 17 5
Apoptosis
NM_006290 TNFAIP3 Tumor necrosis factor, alpha-induced protein 3 7
BG260394 SNCA Synuclein, alpha 8 5
Receptor
NM_021913 AXL AXL receptor tyrosine kinase 12
NM_000142 FGFR3 Fibroblast growth factor receptor 3 35
Others
NM_000104 CYP1B1 Cytochrome P450, subfamily I 7
NM_003118 SPARC Secreted protein, acidic, cysteine-rich (osteonectin) 7
NM_007150 ZNF185 Zinc finger protein 185 (LIM domain) 5
BF213279 FARP1 FERM, RhoGEF (ARHGEF) pleckstrin domain protein 1 8
NM_014903 NAV3 Neuron navigator 3 21 18
M58026 CALML3 Calmodulin-like 3 11
BF217861 MT1E Metallothionein 1E 15 23
NM_020672 S100A14 S100 calcium-binding protein A14 7 12
NM_024593 FLJ11767 Hypothetical protein FLJ11767 6
NM_000396 CTSK Cathepsin K (pycnodysostosis) 10 7
NM_016081 KIAA0992 Palladin 6
NM_005785 RNF41 Hypothetical SBBI03 protein 6
NM_004900 APOBEC3B Apolipoprotein B 8 7
AF088867 AGR2 Anterior gradient 2 homolog (Xenepus laevis) 32 88
AF010316 PTGES Prostaglandin E synthase 7 6
NM_002281 KRTHB1 Keratin, hair, basic, 1 17
U10691 MAGEA3 Melanoma antigen, family A, 6 11
AU145365 — Clone HEMBA1004629, mRNA sequence 7
AK025430 — Hypothetical protein FLJ21777 5
NM_024554 PGBD5 Piggybac transposable element derived 5 31
NM_018436 ALLC Allantoicase 5
NM_025143 C21orf96 Hypothetical protein FLJ20856 5
W72694 LOC51063 Hypothetical protein LOC51063 8
Only genes whose expression changed by five-fold or more and P-value of 0.001 or less are listed.
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view to focus on the genes that are most grossly affected. As a
result, an overall comparison of transcript levels from PM1 vs
MET1, PM1 vs MET4 and MET1 vs MET4 revealed that 82 genes
were significantly differentially expressed with a greater than five-
fold change across the three tumour-derived cell lines that fell into
diverse functional categories potentially affecting extracellular
and intracellular signalling, proliferation and adhesion (Table 1).
In particular, we noted that the axl tyrosine kinase receptor was
significantly overexpressed in the MET1 relative to PM1 cells, and
was also overexpressed 4.3-fold in Met4 relative to PM1 cells
(Table 1).
Axl mRNA and protein expression in PM1, MET1 and
MET4 cell lines
Quantitative RT– PCR was performed on axl transcripts to support
the findings of the expression profiling. The analysis was carried
out on the RNA prepared for the three biological replicates used in
the Affymetrix analysis. The results shown in Figure 1A support
the data from the chip analysis. Western blotting of cell lysates
showed that Axl protein was also overexpressed in the MET1 and
MET4 lines relative to the PM1 line (Figure 1B).
Immunohistochemical analysis of Axl expression in SCCs
To evaluate the expression of Axl in tumours, we performed an
immunohistochemical study on a panel of SCCs, BCCs and normal
skin biopsies using anti-Axl-specific antibodies. Axl expression
was examined in 17 SCCs (11 well-differentiated and six poorly
differentiated) from 16 individuals (Figure 2). Axl expression in 10
BCCs and nine normal skin samples was also investigated. Mast
cells that showed consistent, strong, cytoplasmic staining were
used in all sections as a positive internal control (data not shown).
Goat IgG, at the same concentration as the anti-Axl goat IgG,
served as a negative control. Normal epidermis had almost no
staining (see Figure 2D) with a mean of 1.3% (95% confidence
interval (CI): 0.3 – 2.3) of epidermal cells staining in each section
examined. The mean percentage of cells staining with Axl in BCC
was 1.3% (95% CI: 0.5 – 2.1%), suggesting that Axl does not have a
significant role in cell signalling in BCC (see Figure 2E).
In contrast to normal skin and BCC, 13 out of 17 SCCs (76%)
had significant Axl expression. The mean percentage of well-
differentiated SCC (SCCW) cells staining with Axl was 21.5
(95% CI: 5.2 – 37.8%). In general, SCC tumour cells exhibited
cytoplasmic staining, although there were a few SCC sections
where membranous staining of individual cells was detectable (see
Figure 2A). Furthermore, one section showed clear heterogeneity
in staining within the SCCW (Figure 2B). The poorly differentiated
SCC (SCCP) (Figure 2C) group displayed less Axl staining than
SCCW, with a mean percentage of cells staining of 10.7% (95% CI:
1.2 – 22.6%). Statistical analysis was performed using Dunnett’s
Method to compare Axl staining in normal skin and tumours.
There was a statistically significant difference between well- and
poorly differentiated SCC compared to normal skin (Po0.01).
There was no significant difference between BCC and normal skin
staining with Axl, suggesting that Axl signaling may be restricted
to SCCs.
DISCUSSION
The deregulation of cellular signalling networks underpins much
of the basic framework of carcinogenic processes. A striking
feature of the expression analysis was the finding that the axl gene
was greatly upregulated in the MET1 cells compared to PM1.
Overexpression of both the mRNA and protein was confirmed in
MET1 cells in subsequent experiments. Our results are supported
by previous studies in murine SCC where increased axl expression
was also noted (Loercher et al, 2004). For this analysis, we have
exclusively focused on genes whose expression was altered more
than five-fold. We cannot rule out at this stage that genes whose
expression was not changed by more than five-fold between the
different cell lines used in this study may play an important role in
determining not only the phenotype of these cells, but also in
tumour progression in vivo.
We then extended the observations on the cell lines to
investigate Axl protein expression in a pilot study of SCC biopsies.
This analysis showed that Axl expression was increased in a
significant proportion of the tumours analysed relative to normal
skin. Although this is a small series of tumours, it not only
validates the approach of using the PM and MET cell lines as a
model system, but also suggests that Axl may be a novel marker
whose overexpression is frequently associated with SCC. Whether
Axl is also overexpressed in other precursor lesions such as actinic
keratoses remains to be investigated. Axl expression was not
observed in BCC biopsies, suggesting that Axl is not involved in
altering signal transduction pathways in these tumours. Axl
overexpression has also been noted previously in a variety of
other cancers including ovarian (Sun et al, 2004), ocular melanoma
(van Ginkel et al, 2004), osteosacroma (Nakano et al, 2003) and
renal (Chung et al, 2003) tumours. Axl has been shown recently to
play an important role in cell migration and proliferation of
human endothelial cells (Holland et al, 2005). Receptors such as
Axl that modulate a number of cellular processes such as growth,
adhesion and migration and that are overexpressed on cancer cells,
makes them targets for the development of novel therapeutics.
Multiple clinical trials have employed novel strategies including
antibodies that are antagonistic to such receptors (Finn and
Slamon, 2003; Emens and Davidson, 2004; Mineo et al, 2004), or
alternatively, low molecular weight inhibitors of the kinase activity
have also been used, including imatinib mesylate (Gleevec)
(Druker, 2004; Pulsipher, 2004; Ross and Hughes, 2004) and
gefitinib (Iressa) (Wakeling et al, 2002; Blackledge, 2003; Black-
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Figure 1 (A) Quantitative RT–PCR of axl gene expression in PM1,
MET1 and MET4 cells. (B) Expression of Axl and Gas6, in PM1, MET1 and
MET4 cells. Protein extracts were prepared from the different cell lines,
separated by SDS–PAGE and Western blotted using specific monoclonal
antibodies as described in Materials and Methods. Equal loading of proteins
was verified by Western blotting of tubulin.
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ledge and Averbuch, 2004; Park et al, 2004; Tanno et al, 2004).
Combination therapy, using both monoclonal antibody together
with drug treatment, has also been evaluated (Huang et al, 2004).
As yet, no specific inhibitors of Axl activity have been described.
Our results suggest that further studies aimed at further
elucidating the potential role of Axl in SCC are merited, as it
may represent a potential therapeutic target for intervention in
skin cancer development.
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